Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
BACKGROUND
Debate continues concerning the relevance of neutralizing antibody (NAb) development on the efficacy of interferon (IFN) therapy in patients with multiple sclerosis (MS). The PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study of subcutaneous IFNbeta-1a showed significant benefit on all efficacy outcomes with no significant impact from NAb development on relapses at 2 years. The 2-year extension permitted longer observation following NAb development.


METHODS
Exploratory post-hoc analyses of pharmacodynamic response and clinical and MRI outcomes were performed on data from 368 patients with relapsing MS treated with IFN from study start, based on NAb status.


RESULTS
Persistent NAbs, above 20 NU/mL, were present in 14% of the 44-microg three times weekly (TIW) and 24% of the 22-microg TIW group over 4 years. NAb development was associated with reduced pharmacodynamic marker induction at 1 year. Over the entire 4 years of study, relapse and disability measures were similar between NAb+ and NAb- patients. However, once NAbs developed, significant differences were noted between NAb+ and NAb- groups, particularly on MRI and relapse measures. The presence of binding antibodies alone did not affect outcome.


CONCLUSIONS
Neutralizing antibody development in interferon-treated patients is correlated with reduced efficacy and is a potential cause for renewed disease activity.
Francis
Gordon S
GS
Serono International, Geneva, Switzerland. gordon.francis@gmail.com
Rice
George P A
GP
Alsop
Jonathan C
JC
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D010919:Placebos; D055502:Secondary Prevention; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D001323:Autoantibodies; D010919:Placebos; D016899:Interferon-beta; D000068556:Interferon beta-1a